A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

This is a Phase 1, open-label, assessor-blind, parallel-group study to evaluate the PK and
tolerability of a single subcutaneous dose of 300 milligram (mg) tralokinumab when delivered
as a 2 milliliters (mL) injection at different flow rates to healthy adult volunteers.

Key Inclusion Criteria:

- Healthy males and females ages 19-65 years

- Body mass index of 19.0-30.0 kilogram per meter square (kg/m^2)

- No clinically significant abnormality

- Vital signs, electrocardiogram (ECG), and laboratory parameters within normal range

- Negative alcohol and drug screens

- Females of childbearing potential who are sexually active with a nonsterilized male
partner must use highly effective contraception

- Nonsterilized males who are sexually active with a female partner of childbearing
potential must use highly effective contraception.

Key Exclusion Criteria:

- Concurrent enrollment in another clinical study where the subject is receiving an
investigational product

- Receipt of any marketed or investigational biologic agent within 4 months or 5
half-lives prior to screening, whichever is longer

- Receipt of any investigational nonbiologic agent within 3 months or 5 half-lives prior
to screening, whichever is longer

- Current use of regular pain-modifying, anti-depressant, anxiolytic, or hypnotic
medication

- History of thrombocytopenia or bleeding disorder or use of anticoagulants

- History of any immunodeficiency disorder or use of immunosuppressive medication.

- History of a clinically significant infection

- History of cancer

- Positive Hepatitis B or C

- Positive HIV